These updated 2016 guidelines deal with the management of dyslipidaemias as an essential and integral part of CVD prevention. The guidance includes sections on: the evaluation of laboratory lipid and apolipoprotein parameters; treatment targets; lifestyle modifications to improve the plasma lipid profile; drugs for treatment of hypercholesterolaemia and hypertriglyceridaemia; drugs affecting HDL-cholesterol; managing dyslipidaemias in different clinical settings; monitoring lipids and enzymes in patients on lipid-lowering therapy; and strategies to encourage adoption of healthy lifestyle changes and lipid-modifying therapies.
Publication in full
- Atherosclerosis (2016)
DOI: http://dx.doi.org/10.1016/j.atherosclerosis.2016.08.018 - Eur. Heart J. (2016)
DOI: http://dx.doi.org/10.1093/eurheartj/ehw272 First published August 27, 2016 - Download full pdf
